Skip to main content

Table 5 Changes of QLQ-BN20 over time by performance status

From: Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran

  KSP  
  Worsening Stable Improved P value (ANCOVA)
N = 59 N = 49 N = 79
  Mean (SD) Mean (SD) Mean (SD)  
Headaches * 12.4 (29.2) 1.2 (35.4) -10.0 (32.6) 0.04
Motor dysfunction* 6.1 (18.8) 0.1 (18.2) -4.3 (15.4) 0.01
Drowsiness 5.5 (23.2) 2.4 (27.3) 1.7 (24.3) 0.38
Weakness of legs*† 15.2 (28.4) -1.3 (20.2) -12.1 (19.3) <0.01
Visual disorder 5.4 (16.1) 2.7 (25.4) 1.6 (22.3) 0.64
Bladder control*† 9.6 (18.8) -0.7 (28.9) -6.6 (26.3) 0.01
Seizures 5.3 (19.8) 3.2 (21.8) 2.7 (17.6) 0.72
Hair loss 12.4 (29.2) -4.5 (50.4) -15.2 (45.4) 0.08
Itchy skin* 6.5 (20.8) 0.4 (26.4) -3.8 (24.8) 0.02
  1. * P < 0.05 Improved Vs. Worsening Group.
  2. † P < 0.05 Stable Vs. Worsening Group.